Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | TDO2 | P48775 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535353 | 0.79 | TSHR (0.50) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL1573440 | 0.75 | TSHR (0.60) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL7562082 | 0.75 | TSHR (0.60) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL5006070 | 0.74 | TSHR (0.46) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL21994332 | 0.74 | TSHR (0.46) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL3754314 | 0.74 | ADRB2 (0.56) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL6896036 | 0.74 | ADRB2 (0.56) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL3745333 | 0.74 | ADRB2 (0.56) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL1252993 | 0.74 | TSHR (0.46) | TSHRHIF1AMAPK1TDP1LMNA | |
| SCHEMBL416903 | 0.74 | IDO1 (0.42) | LMNACYP19A1IDO1TDO2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022048-A1 | Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (SPP) to inhibit immune activation, virus replication and tumor growth | LORI FRANCO (US) | 2012-01-26 | — | — | US | claimed |
| WO-2011014239-A1 | ANTI-PROLIFERATIVE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES DERIVATIVES (SPP) TO INHIBIT IMMUNE ACTIVATION, VIRUS REPLICATION AND TUMOR GROWTH | VIROSTATICS SRL (IT) | 2011-02-03 | — | — | WO | claimed |
| US-20120022048-A1 | Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (SPP) to inhibit immune activation, virus replication and tumor growth | LORI FRANCO (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2011014239-A1 | ANTI-PROLIFERATIVE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES DERIVATIVES (SPP) TO INHIBIT IMMUNE ACTIVATION, VIRUS REPLICATION AND TUMOR GROWTH | VIROSTATICS SRL (IT) | 2011-02-03 | — | — | WO | disclosed |
| EP-0718407-B1 | Intermediates for the synthesis of eliprodil enantiomers and process for their preparation | SANOFI SYNTHELABO (FR) | 2002-02-13 | — | — | EP | disclosed |
| EP-0718407-A1 | Intermediates for the synthesis of eliprodil enantiomers and process for their preparation | SYNTHELABO (FR) | 1996-06-26 | — | — | EP | disclosed |
| US-4206235-A | Novel 2,5-dihalophenyl-β-substituted sulfone fungicides | YEDA RESEARCH & DEVELOPMENT CO., LTD. (IL) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022048-A1 | Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (SPP) to inhibit immune activation, virus replication and tumor growth | TYMS, TYMP, PCNA | TSHR 3358/4885HIF1A 2684/4885MAPK1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.